<div id="readability-page-1"><div><figure></figure>The World Health Organization’s recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention on zoonotic respiratory pathogens.Three confirmed fatalities and a widening caseload linked to the South Atlantic itinerary have forced an urgent global response to intercept a pathogen characterized by high lethality and rapid pulmonary onset.Unlike previous isolated incidents, the current multi-country reach of the outbreak has triggered a shift in capital allocation toward biotech and healthcare stocks.Here are three names that stand to particularly benefit from renewed demand for outbreak‑driven vaccine development, diagnostics, and protective‑equipment supply chains.Moderna Inc (MRNA)Moderna shares are the clearest first‑order beneficiary of renewed Hantavirus fears.The biotech already has an early‑stage Hantavirus program in collaboration with USAMRIID and Korea University, giving it a head start if governments accelerate funding for high‑risk pathogen vaccines.The recent Hantavirus outbreak reinforces the value of Moderna’s modular mRNA platform, which can be rapidly adapted to emerging threats.With capital flowing into rapid‑response vaccine names, MRNA stock stands out as the most direct way to play the biosecurity bid.At the time of writing, the Street-high price objective on Moderna currently sits at $135, indicating the stock could shoot up over 150% from current levels as the year unfolds.QuidelOrtho (QDEL)QuidelOrtho stock could benefit as the Hantavirus outbreak lifts demand for rapid, high-sensitivity respiratory diagnostics.The firm’s molecular and antigen testing platforms are already popular among hospitals and public health networks – giving it immediate leverage as authorities expand surveillance for Hantavirus-like symptoms.Any move by governments to broaden screening protocols would directly lift test‑kit volumes and instrument utilization, potentially helping QDEL shares to recover sharply in 2026.In short, with investors rotating into outbreak-sensitive diagnostics, QuidelOrtho offers one of the cleanest ways to play the surge in global pathogen-detection spending.The Street-high price target of $38 suggests it could nearly triple from here over the next 12 months.3M Inc (MMM)3M stock also emerges as a major beneficiary of the Hantavirus outbreak because it revives global demand for high‑grade protective equipment.The firm remains one of the world’s dominant suppliers of N95 respirator, filtration materials, and hospital‑grade barrier products – all of which see an immediate increase in volume when respiratory pathogens with high fatality rates surface.A potential tightening of public health guidance or expansion of occupational safety protocols may accelerate orders from governments and healthcare systems.With investors loading up on PPE leaders, 3M offers a straightforward defensive play on outbreak-driven demand, with an added benefit of a rather lucrative 2.81% dividend yield as well.Wall Street currently rates the behemoth at “overweight”, with price targets going as high as $230, indicating potential upside of nearly 60% from current levels.</div></div>

QDEL

MRNA

The recent Hantavirus outbreak aboard a cruise ship has shifted market focus to biotech and healthcare stocks. Three companies poised to benefit are Moderna Inc (MRNA), which has a Hantavirus vaccine program, QuidelOrtho (QDEL), which could see increased demand for respiratory diagnostics, and 3M Inc (MMM), a major supplier of protective equipment. Analysts predict significant stock price increases for all three as global health responses intensify.

Hantavirus outbreak: these 3 stocks are poised to rip higher